John­son & John­son’s Janssen end­ed its col­lab­o­ra­tion and li­cens­ing agree­ments with Bavar­i­an Nordic con­cern­ing vac­cines for he­pati­tis B virus and hu­man pa­pil­lo­mavirus­es.

J&J and the Dan­ish vac­cines biotech will con­tin­ue their tie-up as it re­lates to HIV and Ebo­la, Janssen said Mon­day. The duo an­nounced the HPV pact in De­cem­ber 2015 at a to­tal po­ten­tial val­ue of $171 mil­lion, and the he­pati­tis B and HIV work came via a Ju­ly 2017 agree­ment worth up to $879 mil­lion.

The Big Phar­ma cit­ed the “wide­spread up­take of ef­fec­tive, pre­ven­tive vac­cines” against HPV as rea­son­ing for drop­ping that por­tion of the pair’s col­lab. The com­pa­ny will not con­tin­ue R&D ef­forts on HPV, an in­fec­tious area large­ly cor­nered by Mer­ck’s Gar­dasil.

Mean­while, J&J will con­tin­ue to in­ves­ti­gate he­pati­tis B through its ex­ist­ing pipeline, which in­cludes two Phase II com­bi­na­tion ther­a­py stud­ies. The two com­pa­nies nev­er be­gan a clin­i­cal study us­ing Bavar­i­an Nordic’s so-called MVA-BN vac­cine tech.

“They were not part of our ac­tive pipeline and there was no progress,” a Bavar­i­an Nordic spokesper­son, re­fer­ring to the HPV and he­pati­tis B projects, told End­points News in an emailed state­ment. “We con­tin­ue to have a strong col­lab­o­ra­tion with Janssen via our joint Ebo­la fran­chise as well as the ear­ly stage HIV project.

The small­pox vac­cine mak­er al­so has a Phase III study in res­pi­ra­to­ry syn­cy­tial virus, a late-stage Covid-19 vac­cine boost­er and an ear­ly-stage open-la­bel tri­al for var­i­ous can­cers.

This comes weeks af­ter Finch Ther­a­peu­tics paused its he­pati­tis B pro­gram and laid off work­ers. Mean­while, Sil­ver­back Ther­a­peu­tics end­ed work on its im­muno-on­col­o­gy pro­gram to shift its fo­cus to­ward a pre­clin­i­cal he­pati­tis B can­di­date as part of the biotech’s own lay­offs weeks ago.

As the House-passed bill to cap the monthly price of insulin at $35 nationwide makes its way for a Senate vote soon, Sanofi announced Wednesday morning that beginning next month it will cut the monthly price of its insulins for uninsured Americans to $35, down from $99 previously.

The announcement from Sanofi, which allows the uninsured to buy one or multiple Sanofi insulins (Lantus, Insulin Glargine U-100, Toujeo, Admelog, and Apidra) at $35 for a 30-day supply effective July 1, follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure.

The FDA’s Vaccine and Related Biological Products Advisory Committee on Tuesday gave the thumbs up — by a vote of 19-2 — that the FDA should require an Omicron-related component in this next season’s booster dose for Covid-19, which both Pfizer/BioNTech and Moderna are hard at work on.

And while neither booster will likely be ready to go with adequate supplies for all American adults by the beginning of the next school year, the situation is still complex and fluid, with CBER Director Peter Marks telling the committee that it’ll take companies at least three months to ready their supplies for this expected next wave.

Indian-based generics manufacturer Aurobindo Pharma has been in the crosshairs of the FDA for several years now, but the company is also attracting attention from regulators within the subcontinent.

According to the Indian business news site Business Standard, a warning letter was sent to the company from the Securities Exchange Board of India, or SEBI.

The letter is related to disclosures made by the company on an ongoing FDA audit of the company’s Unit-1 API facility in Hyderabad, India as well as observations made by the US regulator between 2019 and 2022.

Following some backlash from the American College of Cardiology and patients, Bristol Myers Squibb and Pfizer lowered the price of their blockbuster blood thinner Eliquis, thus ensuring that CVS Caremark would cover the drug after 6 months of it being off the major PBM’s formulary.

“Because we secured lower net costs for patients from negotiations with the drug manufacturer, Eliquis will be added back to our template formularies for the commercial segment effective July 1, 2022, and patient choices will be expanded,” CVS Health said in an emailed statement. “Anti-coagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases.”